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Two principal pathways for apoptosis initiation exist. One pathway, which is also termed the ‘extrinsic’ pathway, is mediated by death
receptors, a subgroup of the TNF receptor superfamily. The second pathway, which is also referred to as the ‘intrinsic’ pathway, is controlled
by members of the Bcl-2 family. A long—standing discussion revolves around the question of how these two pathways influence each other
in regulating the decision about life or death of a cell. Here, we review our current knowledge about the interactions between these two
pathways and discuss current models which could help to resolve previous apparently contradictory results.
D 2003 Elsevier B.V. All rights reserved.Keywords: Apoptosis; Bcl-2 family; Death receptorApoptosis is the physiological form of cell death which
has evolved to allow for tissue remodeling and homeostasis
and to remove superfluous and potentially dangerous cells
from an organism. Processes involving apoptosis are, e.g.
the shaping of the body, removal of activated immune cells
after an infection and deletion of oncogenically or virally
transformed cells [1–4].
Apoptosis is characterized by the ordered destruction of
cellular proteins and DNA, rendering the cells ready to be
taken up by phagocytosis [5]. Key to this ordered destruc-
tion is the activation of a class of proteases, known as
caspases.1. Two converging pathways of apoptosis initiation
Two principal pathways for apoptosis initiation exist. One
pathway which is also termed the ‘extrinsic’ pathway is
mediated by death receptors, a subgroup of the TNF receptor
superfamily. The second pathway, which is also referred to as
the ‘intrinsic’, or possibly more accurate, ‘Bcl-2-controlled’
pathway is consequently controlled by members of the Bcl-2
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the activation of a cascade of proteolytic enzymes, members
of the caspase family.
All caspases are synthesized as zymogens (procaspases)
sharing a common domain structure consisting of a large
(p10) and a small (p20) catalytic subunit (for in-depth reviews
of caspases, see Refs. [9–13]). The N-terminal prodomain,
however, differs widely between the caspases. Two funda-
mentally different groups can be discerned according to the
architecture of the prodomain [14,15]. The first group, also
termed initiator caspases, is characterized by a long prodo-
main which provides a protein–protein interaction platform.
These prodomains allow for the recruitment of the procas-
pases into an activating protein complex. Long prodomain
caspases are caspases-1, -2, -4, -5, -9, -11 and -12 with an N-
terminal caspase-activating recruitment domain (CARD),
and caspase-8 and -10 with an N-terminal death effector
domain (DED). In contrast to the initiator caspases, the so-
called executioner caspases-3, -6 and -7 lack the large N-
terminal non-enzymatic domain. Their name stems from the
observation that they are responsible for the majority of
cellular destruction during apoptosis. The executioner cas-
pases share their short prodomain with caspase-14, a caspase
which is involved in keratinocyte maturation [16–18]. Cas-
pases-1, -4, -5, -11 and -12 are mainly responsible for
processes other than apoptosis and will not be discussed in
detail.
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caspases in a proteolytic cascade. Long prodomain initiator
caspases and the short prodomain executioner caspases
differ in their modes of activation.
Initiator caspases become activated in specialized pro-
tein complexes whose formation is triggered by distinct
stimuli. The activation complex for caspase-9 is termed the
apoptosome [19]. Caspase-8 and caspase-10 are recruited
to and activated in a complex termed ‘death-inducing
signaling complex’ (DISC) (see below). A somewhat more
enigmatic role is played by caspase-2 for which limited
data is available. The existence of a caspase-2-specific
activation complex has been proposed recently [20], and a
role for caspase-2 in the apoptotic response after DNA
damage has been described [21,22].
The executioner caspases in turn are activated by a two-
step mechanism. First, an initial proteolytic cleavage is
needed, which separates the large from the small subunit.
This cleavage is usually carried out by an active initiator
caspase, mainly DISC-activated caspase-8 and apoptosome-
activated caspase-9 [12]. However, the activity of the
resulting enzyme is still inhibited by its own prodomain.
Removal of the prodomain is a prerequisite for full enzy-
matic activity and occurs in an autocatalytic step [23].
Importantly, this autocatalytic maturation can be inhi-
bited by cellular caspase-inhibitors, the IAPs [24]. IAPS
were first characterized as viral proteins capable of inhibit-
ing apoptosis. Several cellular homologs exist, with XIAP
being the best characterized. XIAP can interact with cas-
pase-3 and caspase-9 and thus inhibit their activation. XIAP
inhibits caspase-3 activation by blocking the removal of the
inhibitory prodomain. Thus, even if active initiator caspases
are present in a cell to cleave the executioner caspases, the
cell does not necessarily undergo apoptosis, as the second
step necessary for maturation of executioner caspases mat-
uration can still be inhibited by IAPs.2. The death receptor pathway—activation of caspases
in the DISC
In the extrinsic, receptor-mediated pathway, cell death is
initiated by stimulation of certain members of the TNF
receptor superfamily, the death receptors [25]. Stimulation
of these receptors leads to the formation of the DISC [26].
Binding of the death receptors by their ligands leads to
intracellular binding of the adaptor-protein FADD to the
receptor. FADD in turn serves to recruit pro-caspases-8 and
-10 into the complex. Close proximity of these proenzymes
in the DISC leads to activation of their catalytic activity,
presumably by an allosteric mechanism, involving dimer-
ization between two caspase-8 or -10 molecules [27–30].
While proteolytic separation of the large and small subunits
is not necessary for activation, it probably enhances the
stability of the dimer once it is released from the DISC.
Although both caspase-8 and caspase-10 are activated in theCD95 DISC as well as in the TRAIL DISC [31–33], they
are not redundant in function [31]. Activation of caspases in
the DISC can be inhibited by a cellular protein, FLICE-
inhibitory protein (cFLIP). Both known splicing variants of
cFLIP, cFLIPL and cFLIPs can be recruited to the DISC and
inhibit caspase-8 and -10 activation [34].3. The Bcl-2-controlled pathway
The intrinsic, cell autonomous pathway is triggered by
activation of caspases from inside the cell. Central to this
intrinsic pathway is the formation of an intracellular cas-
pase-9-activating complex, the apoptosome [19]. A key
player in regulating apoptosome-formation is the mitochon-
drion. The apoptosome forms after cytochrome c is released
from mitochondria. Cytochrome c, together with ATP or
dATP and Apaf-1 recruits caspase-9 to activate it, again by
an allosteric mechanism triggered by dimerization or olig-
omerization of caspase-9 [27,35]. Activated caspase-9, like
the DISC-activated caspases-8 and -10, can trigger the
activation of the executioner caspases by executing the first
catalytic cleavage imperative for their activation.
Examples of events triggering apoptosome formation
include genotoxic stress, cytokine withdrawal and detach-
ment of adherent cells (anoikis) [6]. Common to all these
events is that they lead to a breach in mitochondrial
integrity, associated with an efflux of cytochrome c and
other pro-apoptotic molecules [6].
The integrity of the mitochondrial membrane is regulated
by proteins of the Bcl-2 family [7]. This protein family can
be divided into three groups based on their domain archi-
tecture. It consists of anti-apoptotic members like Bcl-2,
Bcl-XL, Bcl-w, Mcl-1, Bfl-1/A1, which are associated with
the mitochondrial outer membrane, serving to maintain
mitochondrial integrity. The so-called BH3-only proteins,
a second group of Bcl-2 family members, act as sentinels
over various cellular organelles and processes. Under nor-
mal conditions, the BH3-only proteins are inactive. Upon
activation, they act as activators of the third group of Bcl-2
family members, the large pro-apoptotic members Bax,
Bak, Bok (Mtd). These proteins associate with the outer
mitochondrial membrane during apoptosis, breaching its
integrity. Bax and Bak are essential for the BH3-only
proteins to act on mitochondria, as cells deficient in these
two proteins are resistant to apoptosis induced by over-
expression of BH3-only proteins [36–38]. Different apo-
ptotic stimuli lead to the activation of distinct BH3-only
proteins. The mechanisms by which these proteins become
activated are different for each family member. They
include transcriptional upregulation for Noxa and PUMA
(Bbc3), dephosphorylation of Bad after growth factor with-
drawal or release from cytoskeletal elements induced by
UV radiation or anoikis (Bmf) or cytokine withdrawal and
Ca++-flux (Bim) (reviewed by Puthalakath and Strasser
[39]).
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tween the receptor-mediated pathway and the Bcl-2-con-
trolled pathway [40,41]. The pro-apoptotic activity of Bid is
activated by caspase-8-mediated cleavage which induces its
translocation to the mitochondria. Mitochondrially trans-
located Bid in turn has a pro-apoptotic effect. Whether this
is due to direct binding to and oligomerization of Bax/Bak
[42,43] or possibly by binding to pro-survival Bcl-2 family
members is still debated [6]. The concept that apoptosome-
driven caspase-9 activation is an integral component of Bcl-
2 family-regulated apoptosis has recently been challenged.
Marsden et al. [44] demonstrated that Bcl-2-controlled
apoptosis still occurs in cells derived from mice deficient
in either Apaf-1 or caspase-9. The definition of the identity
of the proteins involved in this alternative pathway awaits
further experiments.4. How could a Bcl-2 controlled (mitochondrial)
pathway influence death receptor signaling?
A long-standing discussion revolves around the question
whether a Bcl-2 family-controlled mitochondrial pathway is
required during CD95L-induced apoptosis or not [45–48].
One school of thought classified cells into two types, type I
and type II [45]. Type I cells are characterized by a strong
CD95 DISC formation and subsequent caspase activation.
In these cells, CD95L-mediated apoptosis cannot be
inhibited by overexpression of Bcl-2 or Bcl-XL. In type II
cells, a weak DISC formation and caspase activation is seen
after stimulation of CD95. In these cells, CD95-mediated
apoptosis can be inhibited by overexpression of Bcl-2 or
Bcl-XL [45,46]. This classification was hotly debated, as
some argued that the effects were an artifact caused by the
agonistic CD95-reactive antibodies used for stimulation
which do not reliably mimic the physiological ligand
[47,48]. While the concept held true in experiments using
an artificially stabilized trimeric form of the CD95 ligand
[46], no effect was seen when using an antibody-cross-
linked ligand or membrane-bound ligand expressed on
transfected cells [49,50].
The initial explanation for two distinct cell types with
regard to CD95L-induced apoptosis was based on the
assumption that the apoptosome would form an amplifica-
tion loop which would compensate for weak DISC forma-
tion. As described above, the maturation of executioner
caspases can be inhibited by cellular IAPs, most notably
XIAP. Thus, a scenario is possible, where DISC-activated
initiator-caspases cleave caspase-3, yet apoptosis does not
proceed because cellular XIAP blocks the second caspase-3
maturation step. Bid, which is also cleaved by the DISC-
activated caspases, mediates cytochrome c release which
leads to apoptosome formation and caspase-9 activation.
Activated caspase-9, in turn, also cleaves caspase-3, raising
the levels of ‘primed’ caspase-3. The levels of primed
caspase-3 finally out-titrate XIAP which leaves the addi-tional primed caspase-3 uninhibited. The role of an apopto-
some-mediated amplification loop, however, seemed
important only in a few situations. In agreement with this
concept, studies using Bid-deficient mice showed a resis-
tance to CD95L-induced cell death, at least in some tissues
as the liver [51]. However, arguing against an important role
of the apoptosome in CD95L-induced apoptosis are the
phenotypes of Apaf-1 / and caspase-9 / mice, as cells
derived from these mice are not resistant to CD95L-induced
apoptosis [52–55].
This different requirement for Bid in certain situations,
while the apoptosome seemed dispensable, has long been a
subject of discussion and remained an unresolved conun-
drum. Possible explanations emerged by the recent identi-
fication of new players in the apoptosis field (reviewed by
Vaux and Silke [56]). It was the discovery of two XIAP-
antagonizing proteins, Smac/DIABLO [57,58] and HtrA2/
Omi [59–63] which can help to explain some of the
conflicting results of the past. These proteins which, like
cytochrome c, normally reside in the mitochondrial inter-
membrane space have a pro-apoptotic effect once released.
The mechanism by which this is attained has been eluci-
dated for Smac/DIABLO. This protein interacts with, and
sequesters XIAP to remove its inhibition from caspase-9
and caspase-3. In the case of casape-3 this allows for the
second proteolytic step which fully activates this enzyme.
Less is known about the action of HtrA2/Omi, but it
possibly acts by a similar mechanism as well by its inherent
protease activity. What is the link between these proteins to
death receptor-mediated caspase activation? Intriguingly,
using hepatocytes from Bid / mice, Li et al. [64] have
shown that the release of Smac/DIABLO depends on the
action of Bid. Adrain et al. have shown that Smac/DIABLO
release from mitochondria requires caspase activity and can
be blocked by Bcl-2 [65]. In line with these results, Sun et
al. [65] have shown that in type II cells, the release of
mitochondrial Smac/DIABLO is the decisive cellular event
regulated by Bcl-2/Bcl-XL.
Integrating these findings in the overall scheme of death
receptor- and Bcl-2 family-controlled apoptotic pathways, it
becomes clear that the requirement for mitochondria in
apoptosis is not only to provide apoptosome-activated
caspase-9. Even more important might be the release of
XIAP antagonists which remove the apoptosis-inhibiting
block from caspase-3 (this concept has also recently been
discussed by Bratton and Cohen [66]).
One should be aware, however, that sensitivity to death
receptor-induced apoptosis can be regulated by several fac-
tors, and it is the sum of these factors which decides between
life and death of a cell. The expression levels of Bcl-2 family
members and of IAPs is only one of them (Fig. 1).
On the one end of the spectrum are cells which are very
sensitive to death receptor-mediated apoptosis. In these
cells, sensitivity may be due to high expression of death
receptors, the intrinsic ability of these receptors to be
efficiently stimulated and low or absent expression of
Fig. 1. Crosstalk between the Bcl-2 family controlled and death-receptor pathways to apoptosis. Death receptors activate the initiator caspase-8 (and 10) at the
DISC, which in turn prime caspase-3 for its autocatalytic activation. Activation of caspases in the DISC can be inhibited by cFLIP which recruited to the DISC
complex. Alternatively, low receptor levels, intrinsic properties of the receptors or the expression of decoy receptors may lead to sub-optimal cross-linking and,
thus, DISC formation. At the mitochondrial level, apoptosis is initiated by caspase-9 activation in the apoptosome. Caspase-9 acts in a similar manner as the
DISC activated caspases by priming caspase-3. Apoptosome formation is triggered by cytochrome c release from the mitochondrion. Mitochondrial integrity, in
turn, is regulated by the balance of pro- and anti-apoptotic Bcl family members. The BH3-only protein Bid provides a crosstalk between death receptors and
mitochondria, as it is cleaved and thereby activated by DISC-derived initiator caspases, Primed caspase-3 needs to be further processed in an autocatalytic
manner for full enzymatic activity. This step can be inhibited by cellular inhibitors like XIAP which binds to executioner caspases. The XIAP antagonists
Smac/DIABLO and HtrA2/Omi, when released from the mitochondria, relieve this inhibition and allow for apoptosis to proceed.
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contribute to reduced sensitivity, like FLIPs or IAPs are
low or absent. For these cell types, weak stimuli are
sufficient to commit these cells to death. A notable contri-
bution of factors released from mitochondria is predicted to
be absent in these cells and thus, no contribution of Bcl-2
family members can be experimentally noted.
On the other end of the spectrum are cells which are hard
to kill by death ligands. On the receptor level, this can be
due to low expression of death receptors, their resistance to
cross-linking and possibly expression of inhibitory decoy
receptors. On the intracellular level, these cells are predicted
to express high levels of anti-apoptotic proteins like FLIPs
and IAPs. In these cells, stimulation of death receptors only
results in the initial cleavage of caspase-3, with the auto-
catalytic cleavage step being inhibited. Under these circum-
stances mitochondrial release of pro-apoptotic factors is
required for apoptosis to proceed. Thus, an influence of
Bcl-2 family members can be noted experimentally. Over-expression of Bcl-2 or deletion of Bax would lead to relative
resistance of these cells to a certain death stimulus.
It will immediately become apparent that the experimen-
tal setting used to determine ‘sensitivity’ versus ‘resistance’
of a cell type is also important. Differences in apoptosis
sensitivity are most faithfully determined if careful titrations
of the death-inducing stimuli are performed. Otherwise,
differences which might well be physiologically relevant
could go unnoticed.
Crosstalk does not only exist between the death receptor
pathway and the Bcl-2-controlled pathway. It is important to
note that elements which are upstream of the intrinsic
pathway might also influence the death receptor pathways.
Most prominent is the activation of the tumor-suppressor
p53, which can lead to an upregulation of some death
receptors and thus sensitization to apoptosis mediated via
death receptors. Due to space-constraints, we refer the
interested reader to some in-depth reviews of this issue
[67,68].
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TRAIL (Apo-2L) is a cytokine belonging to the TNF-
cytokine superfamily based on its homology to CD95L
[69,70]. Four membrane-bound receptors belonging to the
TNF receptor superfamily have been identified (reviewed by
MacFarlane [71]). Two of these receptors, TRAIL-R1 and
TRAIL-R2 can mediate an apoptotic signal by virtue of their
intracellular death domain. Two other receptors, TRAIL-R3
and TRAIL-R4 have been proposed to act as decoy receptors.
The initial events after triggering the two TRAIL-death
receptors, TRAIL-R1 and TRAIL-2, are well characterized.
With respect to the kinetics of assembly and the intracellular
molecules involved, the TRAIL DISC is very similar to the
CD95 DISC. The TRAIL DISC also utilizes the adaptor
protein FADD/MORT1 and the initiator caspases-8 and -10
for apoptosis induction [31,33,72–74]. In addition, recruit-
ment of cFLIP into the TRAIL-DISC has also been shown
[75].6. Intracellular factors determining sensitivity to TRAIL
Considering what is currently known about the signal-
ing molecules used by TRAIL, it would not be surprising
that the same concept that emerges for CD95 could also
be applied to TRAIL. Several studies addressed the
question of whether a Bcl-2 family-controlled pathway
can also influence TRAIL-mediated apoptosis in a manner
similar to CD95L-induced apoptosis.
In a number of studies, ectopic overexpression of Bcl-2
or Bcl-XL has been found to inhibit TRAIL-induced
apoptosis [76–82]. In certain situations overexpression of
Bcl-2 or Bcl-XL was not able to prevent but rather delay
TRAIL-induced apoptosis [83–85]. Further information
was provided by studies utilizing tumor cells bearing a
mutation in Bax. LeBlanc et al. [86] have shown that this
mutation results in resistance to TRAIL and that treatment
of xenografted Baxwt tumors with TRAIL selects for Bax
mutations in vivo. These results are in line with the
observations of Deng et al. [87] who also showed an
absolute requirement for Bax in TRAIL-mediated apopto-
sis. In this study, it was also proposed that it is the
mitochondrial release of Smac/DIABLO which is the
important event mediated via Bax. Similarly, melanoma
cells can obtain resistance to TRAIL by an XIAP-mediated
block of caspase-3 activation [88]. Srinivasula et al. [89]
have shown that in certain situations overexpression of
anti-apoptotic Bcl-XL inhibits TRAIL-induced apoptosis,
which in turn can be overcome by expression of cytosolic
Smac/DIABLO. The ability of Smac/DIABLO to enhance
TRAIL-induced apoptosis was confirmed by several other
authors using ectopic overexpression of Smac/DIABLO
[90–93]. Another approach demonstrated that cell-perme-
able SMAC-peptides could overcome TRAIL-resistance in
malignant gliomas xenografted into mice [94]. Theseresults suggest an important role of mitochondrially re-
leased Smac/DIABLO and possibly HtrA2/Omi in remov-
ing an XIAP-mediated block in caspase activation.
Experiments using primary human keratinocytes in addi-
tion suggested a role for XIAP in regulating TRAIL
resistance in non-transformed cells [95]. Together, these
experiments hint at an important role for XIAP and its
antagonists Smac/DIABLO, and possibly, Omi/HtrA2 in
regulating TRAIL sensitivity. However, the generation of
mice deficient for XIAP revealed no apparent sensitization
to different pro-apoptotic stimuli in cells derived from
these mice [96]. Several explanations, apart from the
possibility that XIAP plays only a minor role in apoptosis
regulation, could be provided. First, a marked upregulation
of cIAP-1 and cIAP-2 which might compensate for the
loss of XIAP was noted in the XIAP-deficient mice.
Second, the only death receptor stimuli that were tested
were TNF and CD95L. Additionally, no titrations of the
ligands were performed and only a limited number of cell
types were investigated. Thus, it could well be that
potential differences in apoptosis sensitivity went unno-
ticed. Similarly, cells derived from mice deficient in Smac/
DIABLO did not show a marked resistance to death
stimuli, although in an in vitro assay, caspase-3 activation
was impaired [97]. However, for the analysis of TRAIL-
induced apoptosis, titrations were not performed. Whether
the phenotype of these mice speak against an important
role of XIAP or whether the loss of XIAP is compensated
by related molecules awaits further experiments. Apart
from the regulation at the Bcl-2-controlled level, other
factors can also contribute to resistance versus sensitivity
to TRAIL (and possibly other death ligands). It has been
shown that high levels of cFLIP can contribute to resis-
tance of primary B cell chronic lymphocytic leukaemia (B-
CLL) to TRAIL by blocking caspase-8 activation at
the DISC [71,98]. In contrast, in TRAIL-resistant melano-
ma cells the expression and localization of TRAIL death
and decoy receptors seems to be determining resistance
(reviewed by Hersey and Zhang [99]).7. Final words
The influence of Bcl-2 family members on death
receptor-mediated apoptosis was first identified in the
context of experiments which led to the formulation of
the type I versus type II theory with regards to CD95-
mediated apoptosis. It has now become clear that the
concept is valid but that the molecular basis is possibly
broader than initially thought (Fig. 1). In that respect, the
very same cell that is type I for one cell death system can
be of type II for another cell death system, as receptor
levels or the ability of the receptors to be cross-linked may
be different for, e.g. CD95 on the one hand, and TRAIL
receptor system on the other hand. Such different receptor
levels may translate in more or less initiator caspase
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IAP levels by activating enough caspase-3. Thus, in a cell
line where DISC-generated initiator caspase activity is
insufficient to fully activate enough caspase-3 to kill the
cell the cleavage of Bid and the resulting release of
mitochondrially sequestered Smac/DIABLO are necessary
for full caspase-3 activation and apoptosis to occur. While
we seem to understand this downstream mechanism quite
well, our knowledge of how exactly initiator caspase
activation is regulated at the DISC and of how tBid
induces the mitochondrial changes that allow for the
release of apoptogenic factors is still incomplete. It will
be fascinating to see how the molecular details of these
two decisive aspects of the biology of death will be
revealed in the future.References
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